Welcome to the WCN 2021 Interactive Program

The congress will officially run on Central European Time (CET) - Rome Time 
To convert the congress times to your local time 
Click Here

    Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end

     The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform

Browsing Over 213 Sessions

Free Communication
Session Time
11:30 - 13:00
Room
Free Communication B
Chair(s)
  • Claudia Trenkwalder (Germany)
Free Communication
Session Time
11:30 - 13:00
Room
Free Communication C
Chair(s)
  • Masud Husain (United Kingdom)
Break, Poster Viewing and Exhibition Visit

BREAK, POSTER VIEWING AND EXHIBITION VISIT

Session Time
13:00 - 14:00
Room
Exhibition
Sponsored Symposium
Session Time
14:00 - 15:30
Room
Industry 1
Chair(s)
  • Massimo Filippi (Italy)
  • Carlo Pozzilli (Italy)
  • Antonio Uccelli (Italy)
Session Description
Eculizumab as a new therapeutic option in rare neurological diseases
This symposium aims to:
- Spread the knowledge of a pathophysiologic mechanism that not many clinicians know properly, but that is proven to be one of the trigger causes of NMOSD (Neuromyelitis Optica Spectrum Disorder) and gMG (generalized Myasthenia Gravis), two immune mediated rare neurological diseases.
- Present data for eculizumab on both diseases and highlight innovation in therapeutic environment thanks to the discussion with experts.
Sponsored Symposium
Session Time
14:00 - 15:10
Room
Industry 2
Chair(s)
  • Bart Van Wijmeersch (Belgium)
  • Massimo Filippi (Italy)
Session Description
Advancing MS Care: A New Opportunity in High Efficacy Therapy

Join this symposium to learn about the key data that have led to the EMA approval of the subcutaneous use of natalizumab, gain practical insights into using this new route of administration in clinical practice, and keep up-to-date on the latest evidence to maximize the safe, effective use of natalizumab.
The faculty will provide three presentations on the latest advances in treatment with natalizumab followed by a live question-and-answer session. During the session, the online audience can ask questions to the expert panel.

Sponsored Symposium
Session Time
14:00 - 15:30
Room
Industry 3
Chair(s)
  • Cristina Tassorelli (Italy)
Session Description
Envisioning a more inclusive, diverse and equitable global migraine landscape: are we making progress?

During this symposium, we will consider the myriad social determinants of health in general and – focusing on migraine specifically – critique the current state of diversity in clinical studies. We will also review what the latest data tell us about the efficacy and tolerability of monoclonal antibodies targeting the calcitonin gene-related peptide pathway (CGRP mAbs) for migraine prevention across diverse patient subgroups, including different ethnicities, migraine characteristics and comorbidities.
We hope you will join us as we attempt to address this important question: are we making progress towards a more inclusive, diverse, and equitable global migraine landscape?

Session Time
15:30 - 16:15
Room
Plenary
Chair(s)
  • Carlayne E. Jackson (United States of America)

SHORT BREAK

Session Time
16:15 - 16:20
Room
Exhibition
Session Time
16:20 - 17:05
Room
Plenary
Chair(s)
  • William M. Carroll (Australia)

SHORT BREAK

Session Time
17:05 - 17:10
Room
Exhibition
Session Time
17:10 - 18:10
Room
Teaching Course A
Chair(s)
  • James L. Bernat (United States of America)
Scientific Session: MT (Main Topics)
Session Time
17:10 - 18:40
Room
Main Topic A
Chair(s)
  • Mar Tintoré (Spain)